首页> 美国卫生研究院文献>other >Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake
【2h】

Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake

机译:发现双酰胺杂环化合物作为清除剂受体BI(SR-BI)介导的脂质吸收的抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A new series of potent inhibitors of cellular lipid uptake from HDL particles mediated by Scavenger Receptor, Class B, Type I (SR-BI) was identified. The series was identified via a high-throughput screen of the National Institutes of Health Molecular Libraries Small Molecule Repository (NIH MLSMR) that measured the transfer of the fluorescent lipid DiI from HDL particles to CHO cells overexpressing SR-BI. The series is characterized by a linear peptidomimetic scaffold with two adjacent amide groups, as well as an aryl-substituted heterocycle. Analogs of the initial hit were rapidly prepared via Ugi 4-component reaction, and select enantiopure compounds were prepared via a stepwise sequence. Structure-activity relationship (SAR) studies suggest an oxygenated arene is preferred at the western end of the molecule, as well as highly lipophilic substituents on the central and eastern nitrogens. Compound >5e, with (R)-stereochemistry at the central carbon, was designated as probe ML279. Mechanistic studies indicate that ML279 stabilizes the interaction of HDL particles with SR-BI, and its effect is reversible. It shows good potency (IC50 = 17 nM), is non-toxic, plasma stable, and has improved solubility over our alternative probe ML278.
机译:鉴定了一系列新的有效抑制剂,该抑制剂是由清道夫受体B类I型(SR-BI)介导的从HDL颗粒摄取细胞脂质的有效抑制剂。该序列通过美国国立卫生研究院分子图书馆小分子知识库(NIH MLSMR)的高通量筛选进行鉴定,该筛选测量了荧光脂质DiI从HDL颗粒到过表达SR-BI的CHO细胞的转移。该系列的特征是具有两个相邻酰胺基的线性拟肽支架以及芳基取代的杂环。最初的命中类似物可通过Ugi 4组分反应快速制备,选择的对映纯化合物可通过逐步制备。结构-活性关系(SAR)研究表明,在分子的西端首选氧化芳烃,以及在中部和东部氮原子上具有高度亲脂性的取代基。中心碳原子为(R)-立体化学的化合物> 5e 被指定为探针ML279。机理研究表明,ML279可稳定HDL颗粒与SR-BI的相互作用,并且其作用是可逆的。与我们的替代探针ML278相比,它显示出良好的效价(IC50 = 17 nM),无毒,血浆稳定并且具有改善的溶解度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号